Y Intercept Hong Kong Ltd purchased a new position in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 179,722 shares of the company’s stock, valued at approximately $226,000. Y Intercept Hong Kong Ltd owned 0.19% of Gossamer Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Atom Investors LP bought a new stake in Gossamer Bio during the fourth quarter valued at $28,000. AQR Capital Management LLC bought a new stake in shares of Gossamer Bio during the 4th quarter valued at about $31,000. Point72 Hong Kong Ltd purchased a new position in shares of Gossamer Bio during the first quarter worth about $33,000. AXQ Capital LP bought a new position in shares of Gossamer Bio in the fourth quarter worth approximately $36,000. Finally, Principal Financial Group Inc. raised its stake in Gossamer Bio by 25.0% in the fourth quarter. Principal Financial Group Inc. now owns 22,520 shares of the company’s stock valued at $49,000 after purchasing an additional 4,511 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Down 1.0 %

Shares of NASDAQ GOSS opened at $1.01 on Friday. The firm’s fifty day moving average is $1.32 and its 200 day moving average is $1.42. Gossamer Bio, Inc. has a 52 week low of $0.91 and a 52 week high of $15.20. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 17.20. The company has a market cap of $227.58 million, a price-to-earnings ratio of -0.46 and a beta of 1.17.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GOSS shares. UBS Group lowered shares of Gossamer Bio from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $8.00 to $1.25 in a report on Thursday, July 27th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Gossamer Bio in a research report on Thursday, August 10th. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 price objective on shares of Gossamer Bio in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.52.

Get Our Latest Stock Analysis on GOSS

Gossamer Bio Company Profile

(Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Gossamer Bio, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gossamer Bio wasn’t on the list.

While Gossamer Bio currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report